4
Changes in Ownership
Roivant Sciences Ltd. Filed Acc 0001140361-26-035375
President & Immunovant CEO sold 200,000 shares at an average $35.77 ($7,153,393)
- President & Immunovant CEO acquired 200,000 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Venker Eric President & Immunovant CEO | 2026-08-28 | Option exercise 10b5-1 | +200,000 | $3.85 | $770,000 | 1,799,154 | D |
| Venker Eric President & Immunovant CEO | 2026-08-28 | Sale 10b5-1 | −166,182 | $35.63 | $5,921,065 | 1,632,972 | D |
| Venker Eric President & Immunovant CEO | 2026-08-28 | Sale 10b5-1 | −33,818 | $36.44 | $1,232,328 | 1,599,154 | D |
| Derivatives | |||||||
| Venker Eric President & Immunovant CEO | 2026-08-28 | Option exercise · Stock Option (Right to Buy) 10b5-1 | −200,000 | 3,844,834 | D | ||
| Open-market sales · 200,000 sh · avg $35.77 · $7,153,393 | |||||||
Loading xslF345X06/form4.xml…